Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SPHK2 | Q9NRA0 | 7/20 | 0.38 |
| ▸ | SPHK1 | Q9NYA1 | 6/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2472388 | 1.00 | EPHX1 (0.61) | EPHX1TSHRALDH1A1TDP1SPHK2 | |
| SCHEMBL3382033 | 1.00 | EPHX1 (0.61) | EPHX1TSHRALDH1A1TDP1SPHK2 | |
| SCHEMBL250637 | 1.00 | EPHX1 (0.61) | EPHX1TSHRALDH1A1TDP1SPHK2 | |
| SCHEMBL3379496 | 1.00 | EPHX1 (0.61) | EPHX1TSHRALDH1A1TDP1SPHK2 | |
| SCHEMBL3381884 | 0.98 | EPHX1 (0.58) | EPHX1TSHRALDH1A1TDP1SPHK2 | |
| SCHEMBL3378832 | 0.90 | EPHX1 (0.54) | EPHX1TSHRALDH1A1TDP1SMN1; SMN2 | |
| SCHEMBL17199779 | 0.89 | EPHX1 (0.50) | EPHX1TSHRALDH1A1TDP1SPHK2 | |
| SCHEMBL6686097 | 0.88 | EPHX1 (0.50) | EPHX1TSHRALDH1A1TDP1SPHK2 | |
| SCHEMBL12677249 | 0.87 | EPHX1 (0.76) | EPHX1TSHRALDH1A1 | |
| SCHEMBL1526870 | 0.87 | EPHX1 (0.48) | EPHX1TSHRALDH1A1TDP1SPHK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016796-A1 | Pharmaceutical Composition Comprising Mineralocorticoid Receptor Antagonist and Use Thereof | NOVO NORDISK A/S (DK) | 2024-01-18 | — | — | US | disclosed |
| US-11806344-B2 | Pharmaceutical composition comprising mineralocorticoid receptor antagonist and use thereof | KBP BIOSCIENCES PTE. LTD. (SG) | 2023-11-07 | — | — | US | disclosed |
| EP-3517113-A1 | PHARMACEUTICAL COMPOSITION COMPRISING MINERALOCORTICOID RECEPTOR ANTAGONIST AND USE THEREOF | KBP Biosciences Co., Ltd. (CN) | 2019-07-31 | — | — | EP | disclosed |
| US-20190201390-A1 | PHARMACEUTICAL COMPOSITION COMPRISING MINERALOCORTICOID RECEPTOR ANTAGONIST AND USE THEREOF | KBP BIOSCIENCES CO., LTD. (CN) | 2019-07-04 | — | — | US | disclosed |
| EP-2407179-A1 | EXTERNAL PREPARATION CONTAINING ANALGESIC/ANTI-INFLAMMATORY AGENT | Kowa Company, Ltd. (JP) | 2012-01-18 | — | — | EP | disclosed |
| US-20120004305-A1 | EXTERNAL PREPARATION CONTAINING ANALGESIC/ANTI-INFLAMMATORY AGENT | KOWA CO., LTD. (JP) | 2012-01-05 | — | — | US | disclosed |
| US-20120004306-A1 | EXTERNAL PREPARATION CONTAINING ANALGESIC/ANTI-INFLAMMATORY AGENT | KOWA CO., LTD. (JP) | 2012-01-05 | — | — | US | disclosed |
| US-20110319399-A1 | EXTERNAL PREPARATION CONTAINING ANALGESIC/ANTI-INFLAMMATORY AGENT | KOWA CO., LTD. (JP) | 2011-12-29 | — | — | US | disclosed |
| EP-2078058-B1 | SURFACE-MODIFIED ZINC OXIDE-SILICON DIOXIDE CORE-SHELL PARTICLES | EVONIK DEGUSSA GMBH (DE) | 2010-06-16 | — | — | EP | disclosed |
| US-7718816-B2 | Carboxamide derivative, processes for producing the same, and detergent composition | LION AKZO CO., LTD. (JP) | 2010-05-18 | — | — | US | disclosed |
| US-20100092411-A1 | HYDROPHOBIC ZINC OXIDE POWDER | EVONIK DEGUSSA GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
| US-20100040567-A1 | SURFACE-MODIFIED ZINC OXIDE-SILICON DIOXIDE CORE-SHELL PARTICLES | EVONIK DEGUSSA GMBH (DE) | 2010-02-18 | — | — | US | disclosed |
| US-20100008872-A1 | SILICA COATED ZINC OXIDE PARTICLES OBTAINABLE BY A FLAME PYROLYSIS PROCESS | EVONIK DEGUSSA GMBH (DE) | 2010-01-14 | — | — | US | disclosed |
| EP-2061723-B1 | OXIDE PARTICLES COMPRISING ZINC AND MANGANESE | EVONIK DEGUSSA GMBH (DE) | 2009-11-18 | — | — | EP | disclosed |
| US-20070010680-A1 | Carboxamide derivative, processes for producing the same, and detergent composition | LION AKZO CO., LTD. (JP) | 2007-01-11 | — | — | US | disclosed |
| EP-1219701-B1 | Transparent bar soap composition | SHISEIDO HONECAKE INDUSTRY CO (JP) | 2005-01-19 | — | — | EP | disclosed |
| US-6656893-B2 | Sodium salt or a mixed sodium/potassium salt of a fatty acid, amphoteric surfactant; a nonionic surfactant, and at least one glycerin derivative. | SHISEIDO HONECAKE INDUSTRY CO., LTD. (JP) | 2003-12-02 | — | — | US | disclosed |
| US-20020132743-A1 | Transparent bar soap composition | P&PF CO., LTD. (JP) | 2002-09-19 | — | — | US | disclosed |
| EP-1219701-A1 | Transparent bar soap composition | Shiseido Honecake Industry Co., Ltd. (JP) | 2002-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010680-A1 | Carboxamide derivative, processes for producing the same, and detergent composition | FAAH2, FAAH, NAAA | EPHX1 711/4885TSHR 3235/4885ALDH1A1 1474/4885 |
| US-20020132743-A1 | Transparent bar soap composition | SGMS1, PHOSPHO1, SGMS2 | EPHX1 732/4885TSHR 4069/4885ALDH1A1 1921/4885 |
| US-20100040567-A1 | SURFACE-MODIFIED ZINC OXIDE-SILICON DIOXIDE CORE-SHELL PARTICLES | ZKSCAN2, BET1, ZRANB2 | EPHX1 3871/4885TSHR 2643/4885ALDH1A1 4596/4885 |
| US-20100092411-A1 | HYDROPHOBIC ZINC OXIDE POWDER | SLC30A7, SLC39A3, SOD1 | EPHX1 4229/4885TSHR 3477/4885ALDH1A1 4342/4885 |
| US-20240016796-A1 | Pharmaceutical Composition Comprising Mineralocorticoid Receptor Antagonist and Use Thereof | NR3C2, MC2R, REN | EPHX1 2080/4885TSHR 333/4885ALDH1A1 2636/4885 |
| US-20190201390-A1 | PHARMACEUTICAL COMPOSITION COMPRISING MINERALOCORTICOID RECEPTOR ANTAGONIST AND USE THEREOF | NR3C2, MC2R, REN | EPHX1 2080/4885TSHR 333/4885ALDH1A1 2636/4885 |
| US-11806344-B2 | Pharmaceutical composition comprising mineralocorticoid receptor antagonist and use thereof | NR3C2, MC2R, REN | EPHX1 2080/4885TSHR 333/4885ALDH1A1 2636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.